We believe the best way to address this challenge is to treat a patient with more than one TCR-T simultaneously (what we refer to as “multiplex therapy”). To do this, we are developing an ImmunoBank, a portfolio of TCR-T product candidates designed to elicit an anti-tumor response by simultaneously targeting multiple cancer-specific antigens in tumor cells.

Our vision is to build the ImmunoBank with TCRs that recognize diverse targets and are associated with multiple HLA types to provide a broad array of therapeutic options for patients with various types of solid tumors. We are currently engaged in preclinical development of in vivo-engineered T cells using the TCRs in our ImmunoBank, with the goal of delivering an off-the-shelf T-cell product to patients.